drugset / Trial / NCT00042055
CP-461 for the Treatment of Crohn's Disease
Phase 2
Completed
30 enrolled
Astellas Pharma Inc
Cell Pathways · collabOSI Pharmaceuticals · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
Patients with moderately to severely active Crohn's disease will be treated with oral CP-461 200 mg (2 x 100 mg capsules) twice-daily for 8 weeks. The purpose of this study is to see if CP-461 improves the symptoms of Crohn's disease and/or the patient's quality of life. Patient's safety will be monitored throughout the study.
Timeline
- Start
- 2002-07
- Primary completion
- —
- Completion
- 2003-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CP-461 | Small molecule | 200 mg | Oral |